Microfluidic Fabricated Liposomes for Nutlin-3a Ocular Delivery as Potential Candidate for Proliferative Vitreoretinal Diseases Treatment
Elisabetta Esposito,Elena Pozza,Catia Contado,Walter Pula,Olga Bortolini,Daniele Ragno,Sofia Toldo,Fabio Casciano,Agnese Bondi,Enrico Zauli,Paola Secchiero,Giorgio Zauli,Elisabetta Melloni
DOI: https://doi.org/10.2147/ijn.s452134
IF: 7.033
2024-04-11
International Journal of Nanomedicine
Abstract:Elisabetta Esposito, 1 Elena Pozza, 2 Catia Contado, 1 Walter Pula, 1 Olga Bortolini, 3 Daniele Ragno, 1 Sofia Toldo, 3 Fabio Casciano, 4 Agnese Bondi, 1 Enrico Zauli, 2 Paola Secchiero, 4 Giorgio Zauli, 3 Elisabetta Melloni 4 1 Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, I-44121, Italy; 2 Department of Translational Medicine, University of Ferrara, Ferrara, I-44121, Italy; 3 Department of Environmental Sciences and Prevention, University of Ferrara, Ferrara, I-44121, Italy; 4 Department of Translational Medicine and LTTA Centre, University of Ferrara, Ferrara, I-44121, Italy Correspondence: Elisabetta Esposito; Elisabetta Melloni, Tel +39 0532 455230 ; +39 0532 455936, Email ; Purpose: Proliferative vitreoretinal diseases (PVDs) represent a heterogeneous group of pathologies characterized by the presence of retinal proliferative membranes, in whose development retinal pigment epithelium (RPE) is deeply involved. As the only effective treatment for PVDs at present is surgery, we aimed to investigate the potential therapeutic activity of Nutlin-3a, a small non-genotoxic inhibitor of the MDM2/p53 interaction, on ARPE-19 cell line and on human RPE primary cells, as in vitro models of RPE and, more importantly, to formulate and evaluate Nutlin-3a loaded liposomes designed for ophthalmic administration. Methods: Liposomes were produced using an innovative approach by a microfluidic device under selection of different conditions. Liposome size distribution was evaluated by photon correlation spectroscopy and centrifugal field flow fractionation, while the liposome structure was studied by transmission electron microscopy and Fourier-transform infrared spectroscopy. The Nutlin-3a entrapment capacity was evaluated by ultrafiltration and HPLC. Nutlin-3a biological effectiveness as a solution or loaded in liposomes was evaluated by viability, proliferation, apoptosis and migration assays and by morphological analysis. Results: The microfluidic formulative study enabled the selection of liposomes composed of phosphatidylcholine (PC) 5.4 or 8.2 mg/mL and 10% ethanol, characterized by roundish vesicular structures with 150– 250 nm mean diameters. Particularly, liposomes based on the lower PC concentration were characterized by higher stability. Nutlin-3a was effectively encapsulated in liposomes and was able to induce a significant reduction of viability and migration in RPE cell models. Conclusion: Our results lay the basis for a possible use of liposomes for the ocular delivery of Nutlin-3a. Keywords: Nutlin-3a, liposomes, microfluidic, PVDs, CFFF Graphical Proliferative vitreoretinal diseases (PVDs) are a group of pathologies including proliferative vitreoretinopathy (PVR), proliferative diabetic retinopathy (PDR) and epiretinal membranes (ERM), that are characterized by the development of avascular or fibrovascular proliferative membranes which takes place in different parts of the retina. The onset of PVR is usually related to retinal detachment or ocular trauma. Neovascular age-related macular degeneration (nAMD) also develops membranes, similar to PVDs' membranes, but the trigger for this pathology mainly consists of inflammation or oxidative stress. 1 It has already been proven that retinal pigment epithelial (RPE) cells are deeply involved in PVDs' development, stimulated by cytokines or growth factors released as a consequence of the trigger events. 2 In particular, RPE cells, that in healthy condition are subjected to contact inhibitory effect and have a very low turnover rate, under a stimulatory event, for example retinal detachment in PVR, improve their proliferative and migratory properties, and undergo morphological changes, losing their cellular polarity and assuming a fibroblastoid appearance, leading to the so-called epithelial-mesenchymal transition (EMT). Following these events, RPE cells acquire the ability to invade the inner planes of the retina or the vitreous cavity, create fibrotic membranes and so compromise visual function, leading to vision loss. 2–4 At present, the only effective treatment/therapy for PVDs is the surgical peeling of fibrovascular membranes, as no pharmacological agent has been demonstrated to prevent or ameliorate these pathologies. 3,5 Several treatments for PVR have been proposed and reported in clinical studies, such as irradiation, antiproliferative agents as daunomycin, 5-fluorouracil or mitomycin, or steroids, but currently none of these are widely accepted because of an inappropriate understanding of P -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology